Premium
Caspofungin: A Potential Cause of Reversible Severe Thrombocytopenia
Author(s) -
Lynch Julia,
WongBeringer Annie
Publication year - 2004
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.24.14.1408.43148
Subject(s) - caspofungin , echinocandin , echinocandins , medicine , aspergillosis , adverse effect , refractory (planetary science) , antifungal , candida albicans , amphotericin b , intensive care medicine , microbiology and biotechnology , dermatology , biology , immunology , fluconazole , astrobiology
Caspofungin is an echinocandin agent approved for the treatment of invasive candidiasis and refractory aspergillosis. Compared with amphotericin B, caspofungin has an improved safety profile, but clinical experience with this agent is still accumulating. A 68‐year‐old man developed reversible severe thrombocytopenia, possibly due to caspofungin, after being successfully treated for Candida albicans endocarditis. Given the limited clinical experience with caspofungin, continued vigilance for unusual and serious adverse events associated with the drug is imperative.